Novavax, Inc.

NVAX

Find Out if You Qualify for a Financial Reward by filling out the form below.

Investigation Details

On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company’s combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine. The hold was placed following a “serious adverse event of motor neuropathy” that occurred in a CIC Phase 2 trial participant outside the U.S., who received the vaccine in January of 2023.

Following this news, NVAX’s stock price fell by $2.18 per share, or approximately 17% in premarket trading.

Find More Cases

Ticker Symbol Company Name Deadline
NFE New Fortress Energy Inc. November 18, 2024 View
DPZ Domino's Pizza, Inc. November 19, 2024 View
MGX Metagenomi, Inc. November 25, 2024 View
BMBL Bumble Inc. November 25, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
FNA Paragon 28, Inc. November 29, 2024 View
ELAN Elanco Animal Health Incorporated December 06, 2024 View
IREN Iris Energy Limited December 06, 2024 View
AILE iLearningEngines, Inc. December 06, 2024 View
UPS United Parcel Service, Inc. December 09, 2024 View
EW Edwards Lifesciences Corporation December 13, 2024 View
MAPS WM Technology, Inc. December 16, 2024 View
MAPS WM Technology, Inc. December 16, 2024 View
MAPS WM Technology, Inc. December 16, 2024 View
AIXI Xiao-I Corporation December 16, 2024 View
TD The Toronto-Dominion Bank December 23, 2024 View
EVLV Evolv Technologies Holdings, Inc. December 31, 2024 View
LILM Lilium N.V. January 06, 2025 View